Over the past decade, oncology research has ushered in tremendous advances in the understanding of genes that can mutate and cause cancer. But what, exactly, is going awry with those genes that leads to this destructive disease process? A new analysis focusing on 8,000 proteins involved in colon cancer could provide some answers to that question and new targets for treating the disease.
Researchers led by Pacific Northwest National Laboratory (PNNL) analysed genes and proteins in tissue samples from colon cancer patients, comparing diseased tissue to samples from adjacent healthy tissue. They zeroed in on proteins that are regulated by kinases, which regulate the location and duration of protein activation in the body. Their findings could improve the development of immuno-oncology treatments for colon cancer, they reported in the journal Cell.
Avacta Group Plc (LON:AVCT) principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
